These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 15717997)

  • 1. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
    Coleman RE
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate therapy in the oncology setting.
    Lipton A
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):469-88. PubMed ID: 14662000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
    Cameron D
    Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
    Major PP; Cook R
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
    Lacerna L; Hohneker J
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):150-60. PubMed ID: 14613036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C; Swift R; Goode M; Doane L; Rogers M
    Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
    Body JJ
    Breast; 2003 Aug; 12 Suppl 2():S37-44. PubMed ID: 14659142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.